New drug combo aims to tackle tough lung cancer
NCT ID NCT07154290
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial is testing two experimental drugs, ubamatamab and REGN7075, alone or together, in 300 people with advanced or metastatic non-small cell lung cancer who have already had standard treatments. A third drug, sarilumab, may be used to manage immune-related side effects. The main goal is to see if the drugs can shrink tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ubamatamab and REGN7075 (drugs that help the immune system attack cancer cells), with sarilumab (to manage side effects)
What this could lead to
If successful, this could offer a new treatment option for people with advanced lung cancer who have already tried standard therapies.
What could go wrong
This is a mid-stage trial, so it's not yet proven to work. Side effects from the immune system can be serious, and the drugs may not shrink tumors in most patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED/METASTATIC NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cancer Treatment Centers of America, Phoenix
RECRUITINGGoodyear, Arizona, 85338, United States
-
Franciscan Health
RECRUITINGMunster, Indiana, 46321, United States
-
Sarah Cannon Research Institute
RECRUITINGNashville, Tennessee, 37203, United States
-
The City of Hope Orange County Lennar Foundation Cancer Center
RECRUITINGIrvine, California, 92618, United States
-
The University of Texas MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
-
University of Illinois Chicago
RECRUITINGChicago, Illinois, 60612, United States
-
University of Maryland Greenebaum Comprehensive Cancer Center
RECRUITINGBaltimore, Maryland, 21201, United States
-
University of Tennessee Medical Center
RECRUITINGKnoxville, Tennessee, 37920, United States
-
University of Texas Medical Branch
RECRUITINGGalveston, Texas, 77555, United States
-
Washington University School of Medicine
RECRUITINGSt Louis, Missouri, 63110, United States